^
BIOMARKER:

miR-200b overexpression

Entrez ID:
Related biomarkers:
miR-200b overexpression
NSCLC
pembrolizumab
Sensitive: C3 – Early Trials
miR-200b overexpression
NSCLC
nivolumab
Sensitive: C3 – Early Trials